Novel CRISPR enzymes, methods, systems, and their uses
Patent Information
- Application Number
- JP2023558369
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-03-23
- Filing Date
- 2022-03-23
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-03-23
Smart Images

Figure 0007948725000074 
Figure 0007948725000075 
Figure 0007948725000076
Abstract
Claims
1. An engineered, non-naturally occurring CRISPR-Cas system, The invention comprises a single guide RNA (sgRNA) capable of hybridizing to a target nucleic acid, and a codon-optimized CRISPR-related (Cas) protein having at least 90% sequence identity with SEQ ID NO: 1, wherein the Cas protein is fused to a deaminase, and the Cas protein fusion can bind to the sgRNA and edit the sequence of the target nucleic acid complementary to the sgRNA. CRISPR-Cas system.
2. The CRISPR-Cas system according to Claim 1, wherein the sgRNA comprises a sequence having at least about 90% identity with 5'-GUUUUAGAGCUGUGCUGUUUAAACAACACAGCAAGUUAAAAUAAGGCUUUGUCCGUACUCAAGCUUGCAAAAGCGUGCACCGAUUCGGUGCU-3' (Sequence ID 3).
3. A method for cleaving target nucleic acids in isolated eukaryotic cells, The isolated cells are brought into contact with the CRISPR-Cas system described in claim 1, The Cas9 protein is a Cas9 protein that recognizes a PAM sequence containing 5'-NGG-3', The sgRNA includes a scaffold containing a sequence having at least 90% identity with 5'-GUUUUAGAGCUGUGCUGUUUAAACAACACAGCAAGUUAAAAUAAGGCUUUGUCCGUACUCAAGCUUGCAAAAGCGUGCACCGAUUCGGUGCU-3' (Sequence ID 3), The Cas9 protein can bind to the sgRNA and cause cleavage at a target nucleic acid sequence complementary to the sgRNA. method.
4. A method for modifying the expression of a target nucleic acid in isolated eukaryotic cells, The isolated cells are brought into contact with the CRISPR-Cas system described in claim 1, The Cas9 protein is a Cas9 protein that recognizes a PAM sequence containing 5'-NGG-3', The sgRNA includes a scaffold containing a sequence having at least 90% identity with 5'-GUUUUAGAGCUGUGCUGUUUAAACAACACAGCAAGUUAAAAUAAGGCUUUGUCCGUACUCAAGCUUGCAAAAGCGUGCACCGAUUCGGUGCU-3' (Sequence ID 3), The Cas9 protein can bind to the sgRNA and cause cleavage at a target nucleic acid sequence complementary to the sgRNA. method.
5. A method for modifying the expression of a target nucleic acid in isolated eukaryotic cells, or for modifying a target nucleic acid in isolated eukaryotic cells, The isolated cells are brought into contact with the CRISPR-Cas system described in claim 1, The Cas9 protein is a Cas9 protein that recognizes a PAM sequence containing 5'-NGG-3', The sgRNA includes a scaffold containing a sequence having at least 90% identity with 5'-GUUUUAGAGCUGUGCUGUUUAAACAACACAGCAAGUUAAAAUAAGGCUUUGUCCGUACUCAAGCUUGCAAAAGCGUGCACCGAUUCGGUGCU-3' (Sequence ID 3), The Cas9 protein can bind to the sgRNA and edit a target nucleic acid sequence complementary to the sgRNA. method.
6. i) The target nucleic acid is 5' relative to the protospacer adjacent motif (PAM) sequence; ii) The cleavage in the target nucleic acid is a single-strand break or a double-strand break; iii) The Cas9 protein is either a nuclease or a nicasse; iv) The Cas9 protein is inactive Cas9 (dCas9), v) The dCas9 protein is fused to the deaminase, and / or vi) The Cas9 is operably bound to a promoter sequence for expression in eukaryotic cells, The sgRNA is operably bound to a promoter sequence for expression in eukaryotic cells. The method according to any one of claims 3 to 5.
7. (i) The codon-optimized CRISPR-related (Cas) protein comprises a nuclear localization sequence (NLS) and / or a FLAG tag, HIS tag, or HA tag, (ii) The codon-optimized CRISPR-related (Cas) protein has at least 90% sequence identity with SEQ ID NO: 2, (iii) The Cas protein is fused to the deaminase, (iv) The Cas protein fusion can bind to the sgRNA and edit the target nucleic acid sequence complementary to the sgRNA, and / or The Cas9 protein is inactive Cas9 (dCas9). The CRISPR-Cas system according to claim 1 or 2.
8. The CRISPR-Cas system according to claim 7, wherein the Cas9 protein is operably bound to a promoter sequence for expression in eukaryotic cells, and the sgRNA is operably bound to a promoter sequence for expression in eukaryotic cells.
9. The CRISPR-Cas system according to claim 8, wherein the eukaryotic cells are human cells.
10. The CRISPR-Cas system according to claim 8, wherein the promoter sequence is a eukaryotic promoter sequence.
11. A vector comprising the system described in claim 1 or 2, wherein the vector is a plasmid vector or a viral vector.
12. The vector according to claim 11, wherein the viral vector is an adeno-associated virus (AAV) vector or a lentiviral vector.
13. The vector according to claim 12, wherein two or more AAV vectors are used to package the system.
14. A system according to claim 1 or 2 for use in providing treatment to a person requiring treatment for a disability or disease, The sgRNA is complementary to at least 10 nucleotides of a target nucleic acid associated with a condition or disease. The Cas protein associates with the sgRNA, The sgRNA binds to the target nucleic acid, A system in which the Cas protein causes cleavage in the target nucleic acid, or the Cas9 is fused to a deaminase to form an inactive Cas9 (dCas9), resulting in one or more base edits in the target nucleic acid, thereby treating the disorder or disease.
15. The system according to claim 14, wherein the sgRNA is complementary to about 18 to 24 nucleotides.
16. The system according to claim 15, wherein the sgRNA is complementary to 20 nucleotides.
17. The system according to claim 14, wherein the system is contained in a plasmid or a viral vector.
18. The system according to claim 17, wherein the viral vector is AAV.
19. The method according to claim 5, wherein the Cas9 protein is fused to an adenosine deaminase domain, a cytidine deaminase domain, or a combination thereof.
20. The method according to claim 19, wherein the editing results in less than 50% indel formation in the target nucleic acid.
21. The method according to claim 20, wherein the editing generates point mutations.
Citation Information
Patent Citations
Evolved CAS9 variants and uses thereof
WO2019168953A1
